American Interest In Infectious Diseases
Weeks before the current outbreak, Curtis Abraham, the correspondent of the London-based New African magazine, had reported that “the US government has stepped up interest in infectious diseases such as the Ebola Virus Disease (EVD) because of their potential use as a weapon of mass destruction by terrorist organisations, state-sponsored actors, and simply deranged individuals.
“EVD is classified by the US Centres for Disease Control (CDC) as a Category A bioterrorism agent.”
According to Abraham: “Biomedical researchers working for the US Army Medical Research Institute for Infectious Diseases (USAMRIID) and partly funded by the US Department of Defence’s Joint Project Manager Transformational Medical Technologies (JPM-TMT), have been developing preventative and curative drugs to combat any possible bioterror threat from EVD and other viruses.
“However, despite lobbying from scientists before the latest outbreak, the drugs have not been put to the test. One leading candidate is TKM Ebola, an anti-Ebola viral therapeutic, developed by the Canadian pharmaceutical company, Tekmira, under a contract with JPM-TMT.
“TKM-Ebola has shown a 100 percent success rate in monkeys. Back in mid-January 2014, Tekmira announced that it had dosed the first subject in a Phase One human clinical trial of TKM-Ebola. The study was meant to evaluate the safety, determination of a safe dosage range, and identify any possible side effects as TKM-Ebola is absorbed in the body of healthy adult subjects.”
Abraham continued: “In March 2014, the US Food and Drug Administration granted TKM Ebola fast track status to speed up its development.
“Dr Ian MacLachlan, Tekmira’s chief technical officer, announced in a paper presented at the 17th meeting of the American Society of Gene and Cell Therapy in Washington DC, that the company had successfully completed the single ascending dose portion of the TKM-Ebola Phase One clinical trial in healthy human volunteers and that there were no ill effects.
“Tekmira expects to complete the Phase One clinical study later this year. Some scientists see the current Ebola outbreak in West Africa as a unique opportunity to greatly advance the search for a cure, and the vaccine is being stockpiled by the World Health Organisation (WHO) for use in emergencies.”
In June this year, the WHO allowed TKM-Ebola to be used on victims of the outbreak in Sierra Leone, Guinea and Liberia.
In his story, Curtis Abraham quoted Dirk Haussecker, a biologist and medical consultant, as having said: “The primary objective of employing TKM-Ebola would be to further the clinical development of this agent.
“This outbreak is the best-case scenario to test this agent in actually infected patients with a side effect being that it would provide an incentive to people to be isolated.”
According to Abraham, TKM-Ebola is not the only promising drug on the horizon. Several groups of biomedical researchers have already identified 150 or so neutralising antibodies against the Zaire strain of the virus, the strain responsible for the current outbreak.
“Some of these anti-Ebola virus antibodies have been used in cocktails and successfully administered to non-human primates. The monkeys survived in spite of being given lethal doses of EVD two days prior to being fed the cocktail.”
Africans with long memories remember that in the past strange disease outbreaks like Ebola and HIV-Aids have occurred in remote, forested parts of the continent when Western scientists have popped up in these areas or are conducting clinical trials of drugs.
Remember How Aids Spread
One remembers the Aids epidemic and how it spread so fast throughout Africa in the 1980s and 90s, yet before 1980 when Aids was first discovered in homosexuals in San Franscisco, USA, Africa knew no Aids.
One school of thought actually holds the belief that HIV-Aids was a US biological warfare experiment went awry, as in 1970 the Congressional Appropriations Committee had sanctioned a 10-year, $10m research into the production of “an organism that does not naturally exist but which will affect the immune system” for use as part of the US germ warfare programme.
The 10 years coincided exactly with the discovery of HIV-Aids in gays in San Francisco. At the time, the disease was called Gay Related Immune Disease (GRID). Years later, with gays protesting, the name changed to HIV-Aids, with the blessing of the American and French governments whose nationals claimed to have jointly discovered the HIV virus.
Later, an unsuspecting and weak-headed Africa became the origin of the HIV virus because the Westerners said so. And the Africans said Amen.
As in the times past, the template has not changed. US scientists, both government and privately funded, are notorious for using unsuspecting human beings, mostly African-Americans, as guinea pigs for the development and testing of germ warfare agents. Or of rushing in with untested drugs to emergency areas such as the current outbreak of Ebola, to test those drugs on victims.
This has lead many Africans to think that these scientists deliberately enter remote areas of Africa, insert the viruses, and then capitalise on the subsequent epidemics to test their drugs. As Dr Julius Lutwama of Uganda’s Virus Research Institute puts it: “My conviction is that if I am on my death bed and there is something that might alleviate my quick death in a condition where nothing conventional is approved, I would go for what is available.”
Precisely. That is why concerned Africans are calling on the US government to come clean on the current outbreak of Ebola in Sierra Leone, Guinea and Liberia and tell the world what its scientists knew about the outbreak.
The voices of these concerned Africans have been strengthened by a report written by Jon Rappoport of Global Research, and published by WordPress.com on August 2 this year.
In the report, Rappoport called for “an immediate, thorough, and independent investigation of Tulane University [USA] researchers and their Fort Detrick associates in the US bio-warfare research community, who have been operating in West Africa during the past several years. What exactly have they been doing? Exactly what diagnostic tests have they been performing on citizens of Sierra Leone?”
Rappoport continued: “Why do we have reports that the Sierra Leone government has recently told the Tulane researchers to stop this testing? Have the Tulane researchers and their associates attempted any experimental treatments (e.g., injecting monoclonal antibodies) using citizens of the region? If so, what adverse events have occurred?”
Rappoport revealed that “the research programme, occurring in Sierra Leone, the Republic of Guinea, and Liberia – the epicentre of the 2014 Ebola outbreak – has the announced purpose, among others, of detecting the future use of fever-viruses as bio-weapons. Is this purely defensive research? Or as we have seen in the past, is this research being covertly used to develop offensive bio-weapons?
“For the last several years, researchers from Tulane University have been active in the African areas [Guinea, Sierra Leone and Liberia] where Ebola [has] broken out in 2014. These researchers are working with other institutions, one of which is USAMRIID, the US Army Medical Research Institute of Infectious Diseases, a well-known centre for bio-war research, located at Fort Detrick, Maryland.”